Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | HTR6 | P50406 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184129 | 1.00 | MAOA (0.55) | MAOAMAOBCALML3HTR6CYP2C19 | |
| SCHEMBL2183807 | 0.88 | F10 (0.50) | MAOAMAOBHTR6GRM2 | |
| SCHEMBL2183799 | 0.88 | F10 (0.50) | MAOAMAOBHTR6GRM2 | |
| SCHEMBL2184784 | 0.85 | GRM2 (0.41) | MAOAMAOBHTR6GRM2 | |
| SCHEMBL6192208 | 0.84 | MAOA (0.57) | MAOAMAOBCALML3HTR6CYP2C19 | |
| SCHEMBL3718329 | 0.83 | HTR6 (0.46) | MAOAMAOBHTR6 | |
| SCHEMBL3718323 | 0.82 | HTR6 (0.45) | MAOAMAOBHTR6 | |
| SCHEMBL5452213 | 0.82 | MAOA (0.50) | MAOAMAOBCALML3HTR6CYP2C19 | |
| SCHEMBL6210958 | 0.81 | MAOA (0.60) | MAOAMAOBCALML3 | |
| SCHEMBL6210952 | 0.81 | MAOA (0.60) | MAOAMAOBCALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741890-B2 | Substituted amides, manufacturing and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110166125-A1 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-2220079-A2 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063028-A2 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166125-A1 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | ARG1, P4HA1, ASS1 | MAOA 297/4885MAOB 111/4885CALML3 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.